Sort   by:  
 Page size 
UnknownEribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI).
Not available
S-EPMC7900694 | biostudies-literature
UnknownPrognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies.
Not available
S-EPMC10225659 | biostudies-literature
UnknownFactors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world.
Not available
S-EPMC11794064 | biostudies-literature
UnknownSNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials.
Not available
S-EPMC10722129 | biostudies-literature
UnknownEfficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial.
Not available
S-EPMC11362642 | biostudies-literature
Sort   by:  
 Page size